Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis BGlobeNewsWire • 12/30/20
Now Could Be the Perfect Time to Buy This Under-the-Radar COVID Vaccine StockThe Motley Fool • 12/30/20
Altimmune: AdCOVID's Potential To Prevent Transmission May Be Key To Ending The PandemicSeeking Alpha • 12/29/20
Clinical hold on COVID-19 vaccine candidate sends Altimmune down 10% (ALT)Business Insider • 12/24/20
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical TrialGlobeNewsWire • 12/23/20
Altimmune (ALT) Files IND for Phase I Study on Coronavirus VaccineZacks Investment Research • 11/26/20
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in DecemberGlobeNewsWire • 11/25/20
Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19GlobeNewsWire • 11/10/20
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business UpdateGlobeNewsWire • 11/09/20
Altimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID™ Intranasal COVID-19 Vaccine CandidateGlobeNewsWire • 10/12/20
Altimmune Presents Highlights of Intranasal COVID-19 Vaccine and Therapeutic Programs – AdCOVID™ and T-COVID™ – at the World Vaccine CongressGlobeNewsWire • 09/28/20
Altimmune: The Late Bloomer Of The COVID-19 Biotech World, The Best Is Yet To ComeSeeking Alpha • 09/17/20